Hello, and welcome to the 908 Devices’ Third Quarter 2024 Financial Results Conference Call. My name is Elliot, and I'll be coordinating your call today. I would now like to hand over to Kelly Gura with the Gilmartin Group. Please go ahead.

Thank you. This morning, 908 Devices released financial results for the third quarter ended September 30, 2024. If you've not received this news release or if you'd like to be added to the company's distribution list, please send an email to [email protected]. Joining me today from 908 is Kevin Knopp, Chief Executive Officer and Co-Founder, and Joe Griffith, Chief Financial Officer. Before we begin, our commentary today will include the presentation of some non-GAAP financial measures. These measures should be considered as a supplement to and not a substitute for GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's earnings press release, which is available in the Investor Relations section of our website. Additionally, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release 908 Devices issued today. For a more complete list and description, please see the risk factors section of the company's Annual Report on Form 10-K for the year ended December 31, 2023 and in its other filings with the Securities and Exchange Commission. Except as required by law, 908 Devices disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, November 12, 2024. With that, I would like to turn the call over to Kevin.

Thanks, Kelly. Good morning, and thank you for joining our third-quarter 2024 earnings call. We ended the third quarter with revenue of $16.8 million, an increase of 17% over the prior year period. However, our financial results fell short of expectations. As we noted in last quarter's earnings call, we expected second-half 2024 growth to be driven by our handhelds, including a number of 20-plus unit placement opportunities internationally and domestically. While we secured many sizable orders and placed a total of 178 handheld devices during the third quarter, placements were less than expected in part due to a compressed spending period resulting from the delay in passing the federal budget and delays with advancing international contracts. In addition, we continue to see softness in the bioprocessing and life science instrumentation market, elongating the sales cycle of our desktop devices. Our prior 2024 guidance contemplated a quicker and sharper recovery in second-half demand, which hasn't yet materialized. Given the muted 2024 spending environment and the delayed opportunity with the ending of the U.S. Government fiscal year, we are appropriately lowering our 2024 revenue guidance to be in the range of $56 million to $58 million representing 11% to 15% growth. Joe will provide more detail on our guidance in a few moments. The end of October marked six months since the closing of our acquisition of RedWave Technology. We continue to be incredibly excited about the union of our two platforms and the rationale for bringing these two companies together remains absolutely unchanged. As a combined company, we are now better equipped to serve our customers by offering a full best-in-class portfolio of innovative handheld devices paired with world-class service, training, and comprehensive decision support. Reflecting back on our learnings over the last six months, combined with the shifting dynamics in the markets we serve across our entire portfolio, it's become even more evident that, operationally our harmonized platform creates a path for further cost efficiency and expanded gross margins for all of our products. We are implementing three structural adjustments to fully realize this. We are at a turning point and believe now is the right time to lead into these changes and accelerate the transformation of 908, as we prepare for 2025 and the growth beyond. First, we will move manufacturing out of Boston by the end of Q3 2025 to our facilities in Morrisville, North Carolina and Danbury, Connecticut, which are lower-cost manufacturing locations. We successfully moved production of our consumable chips to North Carolina earlier this year, and this site will now take on production of our desktop devices. We completed the expansion of our Danbury facility in the third quarter and this site will manufacture all of our handheld devices going forward, including our U.S. Department of Defense AvCat product in partnership with Smith Detection in the potential full rate production phase. Our Danbury site offers a roughly 75% reduction in facility rent costs compared to Boston, and this will be leveraged over time to expand device gross margins for our highest volume products, our handhelds, representing approximately $2.4 million of annual savings starting in 2026. Second, we have right-sized our bioprocessing and life science instrumentation efforts for current market growth. Last week, we took the action to reduce our workforce by 11%, which included positions in sales, marketing, and R&D. This reduction is expected to save approximately $4.2 million annually and importantly enhances our team's agility to capitalize on opportunities as the industry recovers. Third, we're optimizing our full sales organization for new efficiency, focus, and flexibility to quickly take advantage of growth opportunities. For our handhelds, this includes taking a page from the RedWave playbook and efficiently driving device sales through inside sales efforts with virtual demos and leveraging their established Try Before You Buy program, which combined represented about 25% of RedWave sales year-to-date. For desktops, we are leaning further into our strategy to pursue biopharma partnerships with equipment innovators, particularly in the cell and gene therapy space. To expand our account reach, we will step back from our subscale international direct sales team to gain a larger presence through specialized channel partners in the bioprocessing space across Europe going forward. This model has proven effective for our forensics team. With these adjustments, we remain confident in our ability to operate in a lower growth environment and capture the opportunities in front of us, but we're also looking forward and remain excited to create an acceleration of growth, and believe we remain well-resourced to achieve this. With our assessment, we have identified five key elements to accelerate our growth in the near, medium, and long term. One, increasing enterprise adoption of FTIR handhelds. A strength of 908's commercial engine is the ability to penetrate and radiate across government enterprise accounts. Just over the last few months, MX908 was adopted into multiple global enterprise accounts, including the Vietnam Border Guard, the EU Drug Detect Program for Prisons, and the U.S. National Guard Bureau Counterdrug Program. For our FTIR products, we secured initial purchases with the U.S. Coast Guard, U.S. Environmental Protection Agency, and the U.S. Navy in Q3. Now six months into our prospecting, we've identified 100 units of enterprise potential for our FTIR handhelds. These large enterprise opportunities take time, sometimes years to develop, but it's great to see strong initial pipeline development. We're pleased to see RedWave's products, including the newest Explorer device, following MX908 trajectory and making inroads with large government customers, which represents a previously untapped opportunity. We anticipate that our new Explorer product will be a major contributor as year-to-date placements are already double those of all of 2023. Number two, creating an upgrade cycle with the next generation of our MX908 handheld. Over 2,500 MX908 devices have been deployed since its release in late 2017. We're preparing to disrupt the market yet again with the release of a next-generation device within the next two years, offering a step change in performance and simplicity with half the size and weight, a lower cost of goods, and a higher pull-through opportunity. Three, winning the full rate production award for the U.S. Department of Defense AvCat program in partnership with Smiths Detection. We are developing a complementary variant of the MX908 for program-wide adoption across the U.S. Armed Services which represents thousands of units potential. To date, under the low-rate initial production contract, we have delivered approximately 100 units together with Smiths. The next phase is full-rate production, which is anticipated to result in over $10 million annually. The milestone decision is anticipated within the government's 2025 fiscal year. Number four, return of biopharma CapEx spending for novel instruments. Market reports on biopharma R&D spending and the cell and gene therapy outlook give us confidence that the industry will return to growth. The need for novel process analytical tools is fundamental and remains a key point of emphasis for both regulators and frontline workers. Last year, we launched two game-changing process analytical technology or PAT devices Maven and Maverick. While we've had good customer engagement, we've seen prolonged product trials and evaluations. On the positive, our pipeline of engagements for Maven now includes multiple 12-plus unit opportunities across PD and GMP manufacturing, and we expect Maverick to follow suit. We are expecting sequential improvements in desktops for Q4 and expect this pipeline to more significantly convert as funding headwinds lessen over the next 12 months. Five, partner integrations reaching scale. We continue to believe an efficient path to market and scale for our desktop devices is through integration partnerships with the innovators of process equipment. We are working to secure design wins with multiple companies to enable our placements to scale with these partners. We have previously announced projects with Solaris and Terumo BCT and we are progressing well with a pipeline of more than six others across biologics and cell therapies. For Q4, about half of our anticipated desktop orders are a result of this effort, which was started formally only in Q1 this year. Many of these growth elements are now coming into view as a result of the hard work and dedication of our team and the relentless pursuit of our three focus areas: market expansion, portfolio engagement, and operational excellence. For that, I thank our entire team. While we aren't expecting a V-shaped recovery in our demand environment, we see encouraging signs of improvement. Stepping back, strong second half seasonality has been the norm for our handheld portfolio since the 2017 launch of our flagship MX908 device. Our government sales team has done a fantastic job executing on these large, multi-unit government opportunities over the past seven years, delivering a 27% organic revenue growth CAGR between 2018 and 2023. Handheld growth has certainly been and continues to be lumpy at times, evidenced by our Q3 results and expectations into Q4, but the positive trend line is clear and remains clear. New opportunities for growth paired alongside margin expansion opportunities in our fixed cost and manufacturing operations set up 2025 to be a transformative year for us, and we plan to provide additional color related to our growth and margin trajectory in subsequent calls. With that, I'll now turn the call over to Joe for more detail on our financials.

Thanks, Kevin. Revenue for the third quarter 2024 was $16.8 million, up 17% from $14.3 million in the prior year period, primarily driven by an increase in handheld device revenue. This included approximately $3.2 million of RedWave revenue. Excluding RedWave, revenue declined 5% year-over-year. Handheld revenues serving the forensics market was $14 million for the third quarter 2024, up 19% from $11.7 million for the third quarter 2023. This increase was driven primarily by revenue related to our recently acquired FTIR products and an increase in service revenue. We shipped 178 handheld devices in the third quarter, up from 117 devices in the third quarter of 2023, bringing our installed base to 2,796. As a reminder, in the third quarter 2023, we recognized $2.4 million of revenue from our initial low-rate production delivery under the U.S. Department of Defense AvCat program. Our core handheld growth for the third quarter was 20% when we exclude the AvCat delivery and contributions of RedWave in the third quarter of 2024. Revenue from our desktop products serving the life science, instrumentation, and bioprocessing markets for the third quarter of 2024 was $2.8 million, increasing 8% from $2.5 million in the prior year period. Eight desktop devices were placed in the third quarter. We ended the third quarter 2024 with a cumulative handheld and desktop installed base of 3,253 devices, up 20% from 2,714 at the end of the third quarter 2023. Recurring revenue, which consists of consumables, accessories, and service revenue represented 36% of total revenues this quarter and was $6.1 million, a 70% or $2.5 million increase over the prior year period, largely driven by service. Recurring revenue in the third quarter consisted of $3.9 million related to handhelds and $2.2 million related to desktops. REBEL utilization remained at approximately 0.5 kits per month for our active users, which has been a consistent run rate. Looking ahead, we expect recurring revenue for our product portfolio to be in the mid-30s as a percent of product and service revenue for the full year 2024. Gross profit was $8.3 million for the third quarter of 2024 compared to $7.9 million for the prior year period. Gross margin was 50% for the third quarter of 2024 compared to 55% for the prior year period. Adjusted gross profit was $9.3 million for the third quarter of 2024 compared to $8.1 million for the prior year period. Adjusted gross margin was 55% as compared to 57% for the prior year period. The decrease in gross margin was partly due to a higher mix of service revenue and favorable manufacturing variances in the third quarter of 2023. For the first nine months of 2024, adjusted gross margin was 56% as compared to 52% for the prior year period. Over the longer term, we continue to expect volume-based improvements to our gross margins as we achieve better leverage over fixed costs. Additionally, we expect adjusted gross margin to be in the mid-50s for the full year 2024 with further expansion in 2025 and beyond as we consolidate our manufacturing facilities. Total operating expenses for the third quarter of 2024 were $38.5 million compared to $17 million in the prior year period. The increase in operating expenses was driven by a $30.5 million non-cash goodwill impairment charge, the inclusion of operating expenses related to our acquisition of RedWave, and stock-based compensation. This was offset in part by a $12.1 million credit for an adjustment to the valuation of our contingent consideration liability. Excluding the impact of the non-cash goodwill impairment charge and contingent consideration liability, total operating expenses for the third quarter of 2024 increased $3.2 million including a $500,000 increase in stock-based compensation. The additional $2.7 million increase was primarily due to increased costs associated with the RedWave acquisition, our first full quarter of ownership. Net loss for the third quarter of 2024 was $29.3 million compared to $7.1 million in the prior year period. Adjusted EBITDA for the third quarter was a loss of $6.9 million compared to $5.7 million for the prior year period. We ended the third quarter of 2024 with $71.7 million in cash, cash equivalents, and marketable securities with no debt outstanding. We consumed less than $6 million of cash in the quarter and have used $27.6 million in operating cash during the first nine months of 2024. We expect to finish the year with cash, cash equivalents, and marketable securities in the mid-$60 million range. We remain well-resourced to operate in a lower-growth environment and execute on our 2025 transformation into five identified growth drivers. As Kevin shared earlier, in line with learnings from our first six months of RedWave ownership, we have implemented three structural adjustments to create a path for further cost efficiency and expanded gross margins for all of our products. This sets us up for more than $7.5 million of annual savings with approximately $4.2 million starting in 2025. Looking ahead in 2024, we now expect revenue to be in the range of $56 million to $58 million representing reported growth of 11% to 15% over full-year 2023. This compares to our prior range of $63 million to $65 million. Our updated revenue guidance includes the following assumptions. First, we are lowering our revenue guidance for the core 908 business and now expect an 8% to 4% decline over full year 2023. Our previous guidance range included a number of 20-plus unit handheld orders expected to close before the U.S. Government fiscal year-end. A few of these larger deals did not materialize in the third quarter, and in one case, a last-minute reduction in our customers' funding resulted in a smaller multi-unit placement win. Due to delays with the federal budget and based on our customer meetings in October, many of these opportunities are pushing to 2025 and will require a new budget to initiate purchases. The uncertainties of the election have also led to certain customers pausing available spending and a potential changing environment, given a changing administration. Desktops are continuing to experience headwinds in a recovering market for pre-clinical instrumentation, resulting in a reduction in our fourth quarter expectations. We now expect a decline in year-over-year revenue in the low teens versus potential growth. That said, we're encouraged by positive signs of stabilization in our demand environment, and we are tracking towards sequential improvement in desktops in the fourth quarter. Second, we now expect approximately $10 million in 2024 reported revenue from RedWave, which represents approximately 10% pro forma growth and reflects eight months of ownership. This compares to our prior expectations of $11 million. The reduction is mainly due to the timing of international placements, which are requiring a longer sales cycle and more nurturing than first anticipated. On a pro forma basis, assuming RedWave ownership for the full year 2023, our updated revenue guidance implies a 5% to 2% year-over-year pro forma decline. For the full year, we continue to expect adjusted gross margins to be in the mid-50s range, possibly pulling back a bit from our nine-month adjusted gross margin of 56% due to a higher mix of international sales in the fourth quarter of 2024 and timing of our production builds in the year. As Kevin mentioned, we expect 2025 to be a transformational year for 908. We've implemented a number of strategic initiatives targeting a reacceleration of top-line growth, margin expansion, and cost optimization. Combined with an improved market opportunity, we expect 2025 to represent a key transition year, supporting improved growth and scalability. At this point, I would like to turn the call back to Kevin.

Thanks, Joe. I certainly recognize that Q3 orders did not fully meet our expectations requiring a reset on our full year, but our multi-year growth trajectory remains healthy and sustainable. I further recognize that the integration with RedWave is hard work and can be disruptive, but these are near-term impacts and the prize is realizing the clear operational efficiencies and benefits we've outlined and executing on the five identified drivers of growth to transform and scale our business. As we move forward, we will focus on these initiatives, accelerating synergies, further lowering our cost basis, expanding our margin, and driving us towards profitability while being good stewards of cash and importantly setting ourselves up to outperform and win. I'd like to emphasize that we are an innovation-driven company with a robust pipeline of products designed to outperform traditional tools and unlock new critical to life applications. We believe that the strategic update we announced today not only reduces cost but more importantly positions us for sustainable scalable growth as we aim to be the global leader in point of need chemical analysis across forensics, bioprocessing, and life science research. I'm excited and enthusiastic for what lies ahead. With that, we'll now open it up for questions.

Thank you. Our first question comes from Puneet Souda with Leerink Partners. Your line is open. Please go ahead.

Yeah. Hi, everyone. Thanks for the questions here. First one, I understand the challenges of the life sciences end market. We've been seeing that for the last year. But the magnitude of the guide down at this point, even after accounting for AvCat, raises a question if there are structural or competitive issues in the handheld market beyond the agencies that you're selling these products into. I just wanted to understand if it is largely the pushing out of the budgets because of political uncertainty, which is obviously not lost on anyone but just wondering if that is the primary driver or if there is any structural competition that you're seeing in the market. And on the desktop side, how should we think about the recovery in the first half of 2025? You pointed to sequential improvement here. Should we assume that sequential improvement will continue into the first half?

Yes. Thanks, Puneet. Thanks for your questions there. Yeah, absolutely. The life science is one part that I'll get to in a moment, but the handheld placements did, of course, come in light in Q3. And as you pointed out, if we strip out the $2.4 million in AvCat revenues from the prior year period, MX908 actually did see a positive 20% growth in the quarter, and we did see continued traction with multiple enterprise accounts and U.S. International and we are also pleased today to talk about our largest account win here in APAC with the Vietnam Border Guard. So, yeah, I agree that it is more of a timing with budget uncertainty that really came into play here, so some of the orders we saw really fell out of the quarter with that end of the U.S. Government fiscal year. Joe mentioned in his prepared remarks, a little bit around the election, some pausing, just some rethinking there, always some uncertainty that can develop, but absolutely, I don't see any structural, any competitive, or any other dynamic playing out here. These customers all have a very clear need for a certain number of devices, and they're working to get budget to do that in a particular period. In some cases, they were able to win and get an order this quarter, and in some cases, that order was a little bit smaller just due to again lack of timing, visibility, and the ability to actually contract purchases in a very compressed government fiscal year. So no structural change there. From a desktop recovery perspective, yes, it's a little bit like we've continued to see here headwinds in the desktop placements, and largely we haven't seen much change to that, sales cycle taking longer for our novel technology in that preclinical instrumentation space. We did mention that we do expect a quarter-over-quarter step up in desktop device placements in Q4, and that really is being driven around our partnership initiative that we started formally earlier this year, which gives us confidence in that and it's really kind of a force multiplier as those partners win. So that's coming from some of the initial placements.

And I think maybe pretty hitting on first half of 2025 in desktop, there is a bit of Q4 step up each year, with the year-end budget. Each year can vary. So over the first half of ‘24, we're about $2.5 million a quarter, so we'll be able to get to that level in the first half makes sense, but probably not at the Q4 step up level, off of the $2.3 million in Q3.

Okay. Regarding the organization's lean structure, 908 has always been comparatively leaner than most companies in the sector. There was a workforce reduction earlier this year, followed by an additional 11% reduction. I am curious if the organization is appropriately sized for the current circumstances. If the markets were to improve, would you have sufficient staff to take advantage of that opportunity? Additionally, were the workforce reductions primarily in the U.S. or more concentrated outside the U.S.?

Yes, absolutely. Always very sensitive to make sure that we have the capabilities to take on opportunities as they develop. We really believe we do, and we really believe that reducing the workforce was across sales and marketing, and it was across R&D and a little bit in COGS, U.S, but definitely some international for sure. In the case of our desktops, really, we just needed to work on rightsizing that a bit. It's been a rough eight quarters in that life science CapEx environment and the timing of that recovery is still a bit more maybe gradual than a sharp snapback. So with that, we really worked to resize our team there. But we do think we have all the capabilities that we need to drive growth. We are continuing to leverage a direct sales force in the U.S. and we do have a hybrid direct distribution approach that we're now going to lean more on distribution across Europe to get a broader footprint than we've had before. And then distribution in APAC, which has an interesting pipeline. It's really been developing nicely for us. And then on top of that, as we mentioned, we're really pushing on those partnerships, really looking at a way to have a force multiplier on top of our direct efforts. So we believe that we're well-resourced for now and to drive growth in the future. And to be honest, I think by having a sharper focus team, we'll be able to drive efficiencies and just we're now at that point with new products in this environment, you're doing a lot of test and trials, connecting dots, senior-level selling, and I think we're going to be better equipped for that.

We now turn to Matt Larew with William Blair. Your line is open. Please go ahead.

Hi. This is Sam Martin on for Matt Larew, from William Blair. Just two quick questions. One, just focusing in on really how a new administration might really change things on the handheld side in terms of priorities and timing, and just kind of thinking about the different puts and takes there. What sort of impact are you anticipating initially in terms of further reductions, further pullback in spend, and is there any way that this administration could also impact some of the demand and some spending on the desktop side, given their priorities, in terms of funding might be a little bit different? And then on the desktop side, I think you referenced about eight quarters of CapEx weakness in the life sciences space. So just in terms of the rationalization of bioprocessing instruments, so near-term, are you kind of looking across your portfolio and seeing what might be stale, what you might need to cut? And then long-term, is it sort of changing what you invest in and what you're not investing in or how you invest? Thank you.

Yes, absolutely. Starting first with the handheld and the election piece there. Yes, I think when it certainly can cause a little bit of a shift, particularly amongst the middle ranks that are adjusting their priorities depending upon the administration and, of course, across those senior ranks. I think if you look across the DEA and military spending since 2000, you'd see that there's been a consistent low mid-single-digit growth range really regardless of administrations. So I think there are some experts out there predicting that we may have an increase in the U.S. Defense budget, and I think one of the areas that we may see a positive is on the contracting delays. We mentioned part of our Q3 difficulties in getting some of these opportunities closed within that window of time has been that the government has delays in their passing of their budgets each year, and that can last till spring, and then the money actually doesn't reach our customers' accounts until approximately mid-year, and then our customers know what the priority is, and then they know what they have to work on, and they only really have four to five months to get through the purchasing process, which can be quite complex with these larger enterprise opportunities. So I think if you look from the election results and you look at maybe the alignment, House, Senate and the presidential side, you may see that there could be a chance to accelerate some of that process, perhaps get budgets actually done on time at the end of the fiscal year in September. So I think maybe there's more positives than negatives where we're at right now on that. And I think there's also a feeling out there that there might be a pace of acceleration of new tech, and some barriers might go down there. So we'll have to wait and see on that. And there is a ripple effect just regardless of the administration, but obviously international is important to us for our business. That has been a growing percent of our business over time. And now I think with the NATO, with uncertainty and unrest across the Middle East, it does put pressure on NATO countries to step up, and there has been pronouncements there around investments in new major equipment modernization. So I think perhaps internationally there could be some positives as well. In terms of the desktops, most of our desktops are coming from the preclinical area of biopharma, not directly from the startup. We have some, of course, that are NIH funded, but a lot of ours are really focused on developing accounts across the largest top 20 pharma. So I'm not sure I see the direct election correlation that I could speak of in a meaningful way here today, but I hope that gives you some color on your question.

Yes, that's helpful. And then just my second question on really kind of priorities across the desktop portfolio and where you're looking to...

We are really excited about our fresh desktop portfolio, which includes four products, with two released just last year. These are all PAT tools aimed at controlling processes and improving outcomes. We don't anticipate any changes or rationalization of these products. A significant amount of hard work is being put into testing and evaluations. Our Maven pipeline, which we have been developing for a couple of years, is starting to show progress. We are focusing more on GMP deployments and exploring opportunities within our multi-unit orders and pipeline. Our team is dedicated to navigating evaluations and demonstrating how these tools can be implemented across process development and manufacturing.

Our next question comes from Jacob Johnston with Stephens. Your line is open. Please go ahead.

Hi. This is Hannah Hefley on for Jacob. Thanks for taking the questions. On the CGT end market, you've announced a number of partnerships with hardware innovators in your space. How should we think about these relationships driving desktop growth in coming years? And is there any way to frame up any initial contributions from these relationships?

Yes. Thanks, Hannah. Certainly, that area of strategic collaborations and these partnerships in the cell and gene space, but even more broadly with the biologic hardware innovators too. There can be some near-term revenue impact, but we really believe that it creates a lot of value longer-term, as we get through and scale with these partners. We're working to get our technologies designed in, partnered, or in some cases, more of a co-marketing relationship with these organizations, really working to get these new novel technologies developed in by our collaborators. We announced Solaris and Terumo and that we're actively engaged with those accounts, but we're working with a handful of others that are quite exciting to us as well and really trying to get alliances there for the simple automated PET tools that we provide. As you know, cell therapies really need to address cost and access, and we believe we're really directly contributing to that, and we're providing these real-time monitoring solutions, and we really don't have sampling risk on it. So, ultimately, this strategy really should impact our revenue. And I mentioned in Q4, we do expect it to be helpful to us, and those really should be thought of as initial collaborator placements, initial engagements, call it, the first steps with those companies. But this integration strategy could create an inflection point for us, as we go because again it's really an ability for us to scale out in a little more efficient way. And then, yes, so I think it's a great strategic effort for us. It's an effort we started just formally in Q1, and it's already starting to bear fruit, and we've become more and more convinced it's the right thing to layer on to our direct sales.

All right. Thanks. And then, as it relates to desktop demand, have you seen any changes in the competitive landscape for desktops, or do you think that this is still just largely macro-driven? And then, could you update us on how consumable pull-through is trending for desktops?

Yeah. I haven't seen a change in the competitive dynamics. I mean, I think when we think of the macros and look across definitely some encouraging signs with consumable-driven companies and organizations with some of our large tool peer set there and I think that's a positive indicator of things kind of normalizing out, but maybe not a perfect read through for us because our recurring elements of our desktops was about 10% of our total revenues in the quarter and maybe 14% over our first nine months. So consumables are important, but the placements are incredibly needed and to grow. And so, that device placement, life science implementation into preclinical. We've just seen those challenges with prolonged cycles with the availability of CapEx. So I wouldn't say there's any competitive dynamic we've seen. We're not seeing anything or new surprises on that. Of course, we've got new technologies, so you have to always go out and prove your worth compared to what's out there with our MAVEN and our MAVERICK, but nothing new or concerning to report there on my radar.

And from a consumable revenue perspective or recurring revenue, it's really been consistent over quarters in on revenue utilization. It's remained at about half a kit per month for active users, and our recurring revenues in total about $6.2 million for the quarter, with about $2 million of that related to our desktop. So we're seeing a path to being in the mid-30s as a percent of total product and service sales. A lot of that is service driven, but also an important piece is the desktop consumables, which I mentioned, it's about $2 million in the quarter.

All right. Thanks. I'll leave it there.

Our final question comes from Chad Wiatrowski with TD Cowen. Your line is open. Please go ahead.

Hey, guys. This is Chad on for Brendan Smith. Just on the MX908 sort of next gen instrument, what are the main pain points that you're seeing that would drive that replacement cycle among the existing customers? And then beyond that, would the product enhancements also have the chance of expanding that market?

Yeah. Thanks for the question. The next generation of our MX is certainly an exciting one for us. I mean, if you just think of our handheld devices when we launched our MX908, it's now been about seven years, and we were able to have a CAGR of 27% between that 2018 and 2023, so good growth there and now we have over 2,500 actually, more than 2,700 of our MX908 out there. So we really think it is a great opportunity to disrupt that once again and kind of bring an upgrade cycle. These customers do value outside of just CapEx refreshment cycles, which you expect to be in that 7 to 10-year period. We're getting up on that now. But you can also drive some of these cycles earlier in our opinion by operating a step change of things. It could be size, weight, performance in terms of simplicity, workflow, and user operations. We're working to do all those things while trying to do it with a lower cost of goods and having technology and connectivity capabilities in there to help us further have recurring revenue opportunities over time that we can develop on it. So, to us, it's a major new release that will be coming in the next couple of years, and it's absolutely one of our priority R&D projects for us, and we think it should get exciting given the growth we've seen over the last seven years and then the number of placements throughout there. But then in addition, I would say we're very fortunate and pleased that we have a fuller portfolio with the RedWave acquisition. We now have four products across that space, including our Explorer that we made in our prepared remarks that's been growing really, really nicely. So I think all of these help broaden the groups that we can get to, broaden out the number of customers that we can reach, as well as addressing those immediate replacement cycles.

Thanks. And then just on some of the updated commercial strategy, like are these try before you buy programs and approaches that you've taken from RedWave, are these built in place today and able to be executed, or is this going to take a few quarters to build out these technologies and transition them over to the legacy 908 devices?

Yeah. Look. I mean, we're six months into the acquisition. I think we're still very excited about it. We see all sorts of synergies that we tried to articulate today, definitely revenue synergies in addition to cost synergies. Definitely learnings that we can do to better our ability to get more efficiently at these customers. You touched on two that we think are straight out of the RedWave playbook, if you will, Try Before You Buy, more virtual demos, a little bit into your last question as we kind of broaden with the Explorer, the number of customers that can see a need and capability requirement for it helps us get there. So, yeah, one of the three structural adjustments that we're discussing today is really to align all of our sales force efforts, desktop teams, but also within our handhelds team to take advantage of such programs. And you're right, those are preexisting for RedWave products. We're going to look to see how far we can use those, in the MX 908 products, but importantly, making sure that we're embracing and scaling those within the 908 commercial engine for the FTIR products as we go forward. So, yes, it will take some time. Obviously, we're six months in. I think we've made great strides on the integration. We announced some further big steps we're taking today, but yes, a lot more to come.

We have no further questions. I'll now hand back to Kevin Knopp for any final remarks.

Yes. Thank you all. Thank you for joining our call today, and we appreciate it, and have a great day.

Ladies and gentlemen, today's call is now concluded. We'd like to thank you for your participation. You may now disconnect your lines.